Q1 Earnings

Wells Fargo Q1 2026 earnings due April 14 — analysts expect ~10% profit growth. Net interest income benefiting from elevated interest rates and large deposit base. Credit card delinquency trends closely watched for consumer financial stress signs.

Johnson & Johnson Q1 2026 earnings due before market open. Pharma division expected to remain dominant revenue contributor with medtech showing procedure volume recovery. Immunology franchise under scrutiny as biosimilar competition intensifies. Darzalex and specialty drugs driving incremental growth.

Goldman Sachs Q1 2026 beats with 19% profit jump to .49 EPS. Investment banking fees surge 26% year-on-year as M&A advisory returns to markets. Advisory backlog entering Q2 appears robust. Equity underwriting grows as IPO appetite recovers.